https://ntp.niehs.nih.gov/go/15774

TDMS Study 96020-01 Pathology Tables

NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04
Route: GAVAGE                                                                                                     Time: 13:26:15
                                                     31 WEEK SSAC FINAL #1
       Facility:  Battelle Columbus Laboratory
       Chemical CAS #:  TEFBINARYMIX
       Lock Date:  03/27/02
       Cage Range:  All
       Reasons For Removal:    25017 Scheduled Sacrifice
       Removal Date Range:     04/14/99 - 04/15/99
       Treatment Groups:       Include 001    0 NG /  0 UG
                               Include 004    300 NG /100 UG
                               Include 005    300 NG /300 UG
                               Include 006    300 NG /3000 UG
a  Number of animals examined microscopically at site and number of animals with lesion
                                                              Page   1
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 13:26:15  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
DISPOSITION SUMMARY                                                                                                                 
  Animals Initially in Study                          98           80           98           80                                     
  Scheduled Sacrifice                                 16           10           16           10                                     
  Early Deaths                                                                                                                      
  Survivors                                                                                                                         
  Animals Examined Microscopically                    10           10           10           10                                     
____________________________________________________________________________________________________________________________________
 ALIMENTARY SYSTEM                                                                                                                  
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 CARDIOVASCULAR SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 ENDOCRINE SYSTEM                                                                                                                   
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENERAL BODY SYSTEM                                                                                                                
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 GENITAL SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 HEMATOPOIETIC SYSTEM                                                                                                               
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
                                                             Page   2                                                               
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 13:26:15  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
 INTEGUMENTARY SYSTEM                                                                                                               
   Mammary Gland                                      (10)                                   (10)                                   
      Fibroadenoma                                                                            1 (10%)                               
____________________________________________________________________________________________________________________________________
 MUSCULOSKELETAL SYSTEM                                                                                                             
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 NERVOUS SYSTEM                                                                                                                     
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 RESPIRATORY SYSTEM                                                                                                                 
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 SPECIAL SENSES SYSTEM                                                                                                              
   None                                                                                                                             
____________________________________________________________________________________________________________________________________
 URINARY SYSTEM                                                                                                                     
   Kidney                                                                       (1)                                                 
      Nephroblastoma                                                             1 (100%)                                           
                                                             Page   3                                                               
NTP Experiment-Test: 96020-01  INCIDENCE RATES OF NEOPLASMS BY ANATOMIC SITE (SYSTEMIC LESIONS ABRIDGED) (a)      Report: PEIRPT05
Study Type: CHRONIC                          TEF EVALUATION (BINARY MIXTURE; PCB 126/PCB 153)                     Date: 03/03/04  
Route: GAVAGE                                                                                                     Time: 13:26:15  
____________________________________________________________________________________________________________________________________
         SPRAGUE-DAWLEY RATS FEMALE                0 NG /       300 NG /     300 NG /     300 NG /                                  
                                                   0 UG         100 UG       300 UG       3000 UG                                   
____________________________________________________________________________________________________________________________________
TUMOR SUMMARY                                                                                                                       
   Total Animals with Primary Neoplasms (b)                                     1           1                                       
     Total Primary Neoplasms                                                    1           1                                       
   Total Animals with Benign Neoplasms                                                      1                                       
     Total Benign Neoplasms                                                                 1                                       
   Total Animals with Malignant Neoplasms                                       1                                                   
     Total Malignant Neoplasms                                                  1                                                   
   Total Animals with Metastatic Neoplasms                                                                                          
     Total Metastatic Neoplasm                                                                                                      
   Total Animals with Malignant Neoplasms                                                                                           
   Uncertain Primary Site                                                                                                           
   Total Animals with Neoplasms Uncertain-                                                                                          
   Benign or Malignant                                                                                                              
     Total Uncertain Neoplasms                                                                                                      
____________________________________________________________________________________________________________________________________
a  Number of animals examined microscopically at site and number of animals with lesion                                             
b  Primary tumors: all tumors except metastatic tumors                                                                              
                                                             Page   4                                                               
                             ------------------------------------------------------------                                           
                             ----------              END OF REPORT             ----------                                           
                             ------------------------------------------------------------